Erlocip 150 Tablet contains Erlotinib 150 mg, a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib works by selectively inhibiting the EGFR tyrosine kinase, thereby blocking signal transduction pathways involved in the proliferation and survival of cancer cells. This targeted therapy is indicated for patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen and for use in combination with gemcitabine for locally advanced, unresectable, or metastatic pancreatic cancer. Erlocip 150 is administered orally, with dosing tailored according to patient tolerance and clinical response. Common adverse effects include rash, diarrhea, anorexia, and fatigue, which are generally manageable with supportive care. Regular monitoring of liver function tests and dermatologic assessments is recommended during therapy. Erlotinib’s efficacy may be influenced by the presence of specific EGFR mutations, and molecular testing is advised to identify suitable candidates for treatment. Patients should be counseled on potential drug interactions, including those involving CYP3A4 inhibitors or inducers, and advised to avoid smoking, which may reduce drug effectiveness. Erlocip 150 Tablet offers a targeted approach in oncology, improving outcomes in selected patient populations with EGFR-expressing tumors.